on August 12, 2004
Published online before print August 12, 2004, doi: 10.1161/01.ATV.0000142376.30582.ed
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on February 16, 2004
Accepted on July 18, 2004
ADP Receptor P2Y12 Is Expressed in Vascular Smooth Muscle Cells and Stimulates Contraction in Human Blood Vessels
Anna-Karin Wihlborg ;
From the Departments of Cardiology (A.-K.W., L.W., O.O., D.E.) and Cardiothoracic Surgery (A.E., R.G., T.G.), Lund University, Sweden.
* To whom correspondence should be addressed. E-mail: david.erlinge{at}kard.lu.se.
Objective--ADP plays an important role in platelet aggregation by activating P2Y12 receptors. We assessed the hypothesis that P2Y12 receptors are expressed in vascular smooth muscle cells (VSMC).
Methods and Results--P2Y12 receptor mRNA was found to have a high expression among the P2 receptors in human VSMC, significantly higher than the other 2 ADP receptors (P2Y1 and P2Y13, real-time polymerase chain reaction). Western blots gave a band of 50 kD, similar to that in platelets. To unmask a P2Y12 receptor-mediated vasoconstriction by simulating the in vivo situation, vessels were precontracted to a submaximal level. 2-MeSADP stimulated contractions in vessel segments from internal mammary artery (IM), IM branches and small veins (Emax=15±6% of 60mmol/L K+ contraction, pEC50=5.6±0.6, Emax=21±1%, pEC50=6.8±0.1, versus Emax=48±9%, pEC50=6.6±0.4). The selective P2Y12 antagonist AR-C67085 blocked 2-MeSADP contractions. The contraction was not reduced in patients using clopidogrel, a drug inhibiting ADP-induced platelet aggregation by blocking the P2Y12 receptor. This may be explained by the high instability of the active clopidogrel metabolite that never reaches the systemic circulation.
Conclusion--ADP acting on P2Y12 receptors not only is important for platelet activation but also stimulates vasoconstriction. Stable drugs with antagonistic effects on P2Y12 receptors, affecting both platelets and VSMC, could be of double therapeutic benefit in their prevention of both thrombosis and vasospasm.
Key words: vasoconstriction • P2Y receptors • platelets • ADP
This article has been cited by other articles:
 |
|
 |
|
  D.J.W. Evans, L.E. Jackman, J. Chamberlain, D.J. Crosdale, H.M. Judge, K. Jetha, K.E. Norman, S.E. Francis, and R.F. Storey Platelet P2Y12 Receptor Influences the Vessel Wall Response to Arterial Injury and Thrombosis Circulation, January 6, 2009; 119(1): 116 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.J.J. van Giezen Optimizing platelet inhibition Eur. Heart J. Suppl., May 1, 2008; 10(suppl_D): D23 - D29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Graciano, A. Nishiyama, K. Jackson, D. M. Seth, R. M. Ortiz, M. C. Prieto-Carrasquero, H. Kobori, and L. G. Navar Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension Am J Physiol Renal Physiol, January 1, 2008; 294(1): F161 - F169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Abbracchio, G. Burnstock, J.-M. Boeynaems, E. A. Barnard, J. L. Boyer, C. Kennedy, G. E. Knight, M. Fumagalli, C. Gachet, K. A. Jacobson, et al. International Union of Pharmacology LVIII: Update on the P2Y G Protein-Coupled Nucleotide Receptors: From Molecular Mechanisms and Pathophysiology to Therapy Pharmacol. Rev., September 1, 2006; 58(3): 281 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Steinhubl, P. B. Berger, D. M. Brennan, E. J. Topol, and for the CREDO Investigators Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention J. Am. Coll. Cardiol., March 7, 2006; 47(5): 939 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Ferrari, A. la Sala, E. Panther, J. Norgauer, F. Di Virgilio, and M. Idzko Activation of human eosinophils via P2 receptors: novel findings and future perspectives J. Leukoc. Biol., January 1, 2006; 79(1): 7 - 15. [Abstract] [Full Text] [PDF]
|
|